Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Avadel Pharmaceuticals plc (NASDAQ: AVDL).

Full DD Report for AVDL

You must become a subscriber to view this report.


Recent News from (NASDAQ: AVDL)

Avadel Pharmaceuticals plc 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Avadel Pharmaceuticals plc in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 13:33
Avadel Pharmaceuticals' (AVDL) CEO Michael Anderson on Q1 2018 Results - Earnings Call Transcript
Avadel Pharmaceuticals PLC (AVDL) Q1 2018 Earnings Conference Call May 02, 2018, 11:00 ET Executives Lauren Stival - Senior Director, IR and Corporate Communications Michael Anderson - CEO & Director Michael Kanan - CFO & SVP Gregory Davis - EVP & COO Analysts ...
Source: SeekingAlpha
Date: May, 02 2018 16:32
Avadel Pharmaceuticals beats by $0.03, beats on revenue
Avadel Pharmaceuticals (NASDAQ: AVDL ): Q1 EPS of -$0.34 beats by $0.03 . More news on: Avadel Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 02 2018 07:32
Avadel Pharmaceuticals Reports First Quarter 2018 Results
NOCTIVA™ launch underway across the U.S. FT 218 granted Orphan Drug Designation Generated revenue of $33.3 million DUBLIN, Ireland, May 02, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the first quarte...
Source: GlobeNewswire
Date: May, 02 2018 07:30
Avadel Launches NOCTIVA(TM), the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria
DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL) today announced the launch of NOCTIVA™ (desmopressin acetate), an emulsified microdose Nasal Spray. NOCTIVA is the first and only FDA-approved treatment proven to help adults with nocturia du...
Source: GlobeNewswire
Date: May, 01 2018 09:43
Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
DUBLIN, Ireland, April 30, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or “the Company,” today announced that Greg Divis, Chief Operating Officer, and Mike Kanan, Chief Financial Officer, will present at the Deutsche Bank 43rd Annu...
Source: GlobeNewswire
Date: April, 30 2018 16:01
Avadel Pharmaceuticals to Report First Quarter 2018 Results
DUBLIN, Ireland, April 24, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its first quarter 2018 financial results on Wednesday, May 2, 2018, before the market open. A conference call to discuss these results has been scheduled for Wednesda...
Source: GlobeNewswire
Date: April, 24 2018 07:30
Detailed Research: Economic Perspectives on VASCO Data Security International, Constellation Brands, MYOS RENS Technology, Avadel Pharmaceuticals, Energizer, and BJ's Restaurants - What Drives Growth in Today's Competitive Landscape
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of VASCO Data Security International, Inc. (NASDAQ:VDSI), Constellation Bra...
Source: GlobeNewswire
Date: April, 06 2018 07:55
Avadel Offers An Excellent Risk/Reward Profile
Avadel (AVDL) offers an unusual risk/reward profile. Shares of the Ireland-based company have struggled in the last one year, falling nearly 25%. The pullback has been partly due to declining revenue. The delay in NDA filing for FT 218 has also kept shares subdued. However, Avadel is a revenue...
Source: SeekingAlpha
Date: April, 04 2018 11:27
Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA(TM) at the 2018 American Urological Association
DUBLIN, Ireland, April 03, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or the “Company,” today announced that new data from NOCTIVA’s pivotal Phase III clinical trials will be presented at the American Urological Association...
Source: GlobeNewswire
Date: April, 03 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-186.926.987.116.83613,514
2018-05-176.926.987.116.83613,514

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1835,81057,38962.3987Short
2018-05-1742,36079,52753.2649Short
2018-05-1660,97397,89362.2854Short
2018-05-1540,72381,49749.9687Short
2018-05-1452,051138,53237.5733Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AVDL.


About Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Logo for Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Not available

 

Contact Information

 

 

Current Management

  • Stephen H. Willard / CEO
  • Michel Finance / CFO

Current Share Structure

  • Market Cap: $260,351,536 - 05/11/2018
  • Issue and Outstanding: 37,952,119 - 03/09/2018

 


Recent Filings from (NASDAQ: AVDL)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 17 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: May, 04 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 09 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: AVDL)

Daily Technical Chart for (NASDAQ: AVDL)


Stay tuned for daily updates and more on (NASDAQ: AVDL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AVDL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVDL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AVDL and does not buy, sell, or trade any shares of AVDL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/